Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301
Ann Childress, MD, the lead investigator in the phase 3 CTx-1301-022 study, discusses the positive data, recently shared at 2023 Psych Congress. Data show that the novel treatment can last up to 16 hours, helpful for patients with long days.
Other Articles in this Edition
Study shows nearly 300% increase in ADHD medication errors
People over 50 with ADHD ‘overlooked’ for diagnosis and treatment, say experts
Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301
10 Common Mistakes Parents Make When Talking To ADHD Teens About Friendships
Understanding ADHD and Its Impact on Your Practice
5 Unique Ways To Foster Body Positivity In Tweens & Teens — That Work For ADHD Kids, Too
Province to pay private psychologists to address backlog of ADHD, autism testing
ADHD has become an identity, not just a disorder. We need a new way to talk about it